Zura Bio Limited
$5.37
0%
2026-04-21 10:27:00
zurabio.com
NCM: ZURA
Explore Zura Bio Limited stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$491.42 M
Current Price
$5.37
52W High / Low
$7.44 / $0.98
Stock P/E
—
Book Value
$1.38
Dividend Yield
—
ROCE
-74.11%
ROE
-52.49%
Face Value
—
EPS
$-1.06
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
40
Beta
0.24
Debt / Equity
—
Current Ratio
9.05
Quick Ratio
9.05
Forward P/E
-56.5
Price / Sales
—
Enterprise Value
$426.67 M
EV / EBITDA
-5.67
EV / Revenue
—
Rating
Strong Buy
Target Price
$15.5
EPS Forecast (FY)
—
Pros
- Short-term liquidity looks comfortable.
- Valuation is not stretched on P/E basis.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Cartesian Therapeutics, Inc. | $6.94 | — | $183.97 M | — | -30.8% | 195.88% | $15.57 / $5.6 | $-4.85 |
| 2. | Champions Oncology, Inc. | $6.08 | — | $84.36 M | — | 57.07% | -47.59% | $9.63 / $5.5 | $0.31 |
| 3. | Avalo Therapeutics, Inc. | $14.66 | — | $334.08 M | — | -70.45% | -72.44% | $20.72 / $3.39 | $4.49 |
| 4. | Agenus Inc. | $4.42 | 1,529.26 | $175.86 M | — | 21.26% | -0.04% | $7.34 / $1.6 | $-7.68 |
| 5. | Spruce Biosciences, Inc. | $69.89 | — | $96.45 M | — | -85.04% | -1.09% | $240 / $4.28 | $30.99 |
| 6. | TScan Therapeutics, Inc. | $1.43 | — | $67.71 M | — | -64.64% | -71.28% | $2.57 / $0.88 | $2.16 |
| 7. | ProMIS Neurosciences, Inc. | $11.45 | — | $24.63 M | — | 3267.2% | -5.22% | $39.75 / $6.27 | $-0.58 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 0 M | 0 M | 0 M | 0 M | 0 M | — |
| Operating Profit | -18.41 M | -19.52 M | -18.06 M | -19.25 M | -15.73 M | — |
| Net Profit | -17.18 M | -18.04 M | -15.99 M | -17.44 M | -13.62 M | — |
| EPS in Rs | -0.18 | -0.19 | -0.17 | -0.18 | -0.14 | -0.26 |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 0 M | 0 M | 0 M | 0 M |
| Operating Profit | -75.25 M | -55.19 M | -62.64 M | -27.16 M |
| Net Profit | -68.65 M | -52.4 M | -60.36 M | -25.74 M |
| EPS in Rs | -0.72 | -0.55 | -0.64 | -0.27 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 113.95 M | 179.53 M | 100.84 M | 5.26 M |
| Total Liabilities | 12.41 M | 19.51 M | 21.29 M | 27.32 M |
| Equity | 101.54 M | 146.81 M | 59.33 M | -32.06 M |
| Current Assets | 112.31 M | 178.74 M | 100.84 M | 1.78 M |
| Current Liabilities | 12.41 M | 19.51 M | 20.3 M | 14.82 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -64.81 M | -28.08 M | -15.05 M | -1.2 M |
| Investing CF | -0.11 M | -5.08 M | -8 M | -12 M |
| Financing CF | -2.16 M | 109.84 M | 121.29 M | 14.77 M |
| Free CF | -64.93 M | -33.15 M | -23.05 M | -13.2 M |
| Capex | -0.11 M | -5.08 M | -8 M | -12 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Revenue Growth % | — | — | — | — |
| Earnings Growth % | -31% | 13.18% | -134.52% | — |
| Profit Margin % | — | — | — | — |
| Operating Margin % | — | — | — | — |
| Gross Margin % | — | — | — | — |
| EBITDA Margin % | — | — | — | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
No stock split history available.